Preventing Hospital Readmissions in Heart Failure: Results and Successes

Released On
January 23, 2020

Expires On
January 23, 2021

Media Type

Completion Time
30 minutes

Cardiology, Emergency Medicine, Pharmacy, Primary Care


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Purdue University College of Pharmacy and MCM Education..


Supported by an educational grant from Novartis.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)
  • Pharmacists — 0.5 ACPE Contact Hour(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

Cardiologists, emergency medicine physicians, internists, NPs, PAs, pharmacists

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Identify patients with HF who are at greatest risk of health complications and hospitalizations
  2. Develop a coordinated multidisciplinary plan for interventions that have been shown to be effective in reducing 30-day hospital readmissions in patients with HF
  3. Describe the process to implement interventions for performance improvement in reducing 30-day readmissions in patients with HF
  4. Evaluate the effectiveness of interventions implemented to reduce 30-day readmissions for patients with HF


Stuart Russell, MD

Professor of Medicine
Regional Director of Heart Failure
Duke University School of Medicine
Durham, North Carolina

Nisha A. Gilotra, MD

Director, Heart Failure Bridge Clinic
Assistant Professor of Medicine
Division of Cardiology, Section of Advanced Heart Failure and Transplantation
Johns Hopkins School of Medicine
Baltimore, Maryland

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Pharmacist Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-19-099-H01-P, 0.5 contact hours (0.05 CEU).

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Credit Designation

Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.


All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.

  • Dr. Russell has nothing to disclose.
  • Dr. Gilotra has received grants and research support from Intracellular Therapeutics and has been a consultant for scPharmaceuticals. Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports that their presentation will not contain references to investigational and/or off-label uses.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.